Relmada Therapeutics, Inc. develops clinical-stage therapies for oncology and central nervous system disorders. Company news centers on NDV-01, an intravesical sustained-release gemcitabine-docetaxel therapy being evaluated for non-muscle invasive bladder cancer, including clinical data, FDA feedback on registrational study design, and presentations at medical conferences.
Recurring updates also cover quarterly and annual financial results, business progress, healthcare conference participation, and financing activity tied to the company’s clinical development plans.
Relmada Therapeutics (Nasdaq: RLMD) received a Notice of Allowance from the Canadian Intellectual Property Office for its patent on REL-1017, a novel NMDA receptor antagonist. This patent broadens its intellectual property in Canada, a key market for treating psychological disorders such as depression and anxiety. The company is set to initiate its Phase 3 program for REL-1017 in Q4 2020 after receiving FDA clearance to proceed without further trials. REL-1017 showed promising Phase 2 results, demonstrating significant antidepressant effects and a favorable safety profile.